Abstract
Bladder cancer (BC) is among the ten most common malignant tumors worldwide. Tumor stem cells contribute significantly to postoperative recurrence and disease progression. Understanding stem cell interactions with other tissue cells and developing a prognostic model may improve BC management. Through single-cell RNA sequencing, we identified tumor stem cells in BC tissue. We identified 91 genes specifically upregulated in the stem cell cluster versus other clusters. Of these, 67 whose high expression correlated with poorer patient survival were defined as high-risk stemness genes (HRSGs). Further analysis showed that the MDK-LRP1 axis is the primary communication pathway between stem cells and other cell types, involving 31 of these HRSGs. Based on these 31 HRSGs, patients were stratified into two stemness clusters (ST cluster A and B), with ST cluster B associated with poorer prognosis. We further selected prognosis-related genes from differentially expressed genes between the clusters to construct a risk model. Patients in ST cluster B exhibited higher risk scores, aligning with clinical outcomes. Among the HRSGs, ACTN1 emerged as a key gene, showing elevated expression in patients with poor survival and advanced disease stages. Immunohistochemistry confirmed significantly increased ACTN1 protein levels in BC tissues. Additionally, protein interface analysis indicated that the Cys104 residue of Midkine potentially interacts with both LRP1 and ACTN1 within a 5 Å distance, suggesting a critical interaction site. These findings provide novel insights into stem cell-mediated BC progression and offer potential prognostic and therapeutic targets.
Introduction
Bladder cancer (BC) is characterized by high rates of recurrence and progression, largely attributed to the presence of tumor stem cells. These cells are capable of self-renewal and drive the overall malignancy of the tumor. While their existence is well-documented, the specific signaling pathways through which they communicate with the surrounding tumor microenvironment (TME) to promote disease progression have remained poorly understood.
This study addresses this gap by mapping the "communication network" of BC stem cells using single-cell RNA sequencing (scRNA-seq). The researchers identified the Midkine (MDK)-LRP1 pathway as a primary driver of disease progression and developed a high-accuracy prognostic model to better categorize patients and identify novel therapeutic targets.
Workflow and Methodology
The study employed a multi-omic approach to dissect the cellular heterogeneity of bladder cancer.
The methodology integrated several advanced techniques:
- Single-cell RNA sequencing (scRNA-seq): Analysis of over 20,000 individual cells from BC patients allowed for the isolation of rare stem cell populations.
- CellChat Analysis: This tool mapped the signaling pathways (interactome) used by stem cells to communicate with other cell types, such as monocytes and epithelial cells.
- Prognostic Modeling: Using LASSO regression and multivariate Cox analysis on the TCGA-BLCA dataset, a 59-gene risk model was constructed to predict patient survival.
- Protein Interface Analysis: Molecular docking simulations (HDOCK and PyMOL) were performed to understand the physical interactions between key proteins—Midkine (MDK), LRP1, and ACTN1—at the atomic level.
Key Insights and Results
The MDK-LRP1 Communication Axis
The study identified the Midkine-LRP1 axis as the dominant signaling channel between stem cells and epithelial cells. This pathway appears to coordinate the aggressive behavior of the tumor. Within this axis, 31 high-risk stemness genes (HRSGs) were identified as central players.
New Patient Subtypes
By analyzing the expression of these 31 genes, the researchers stratified patients into two new subtypes:
- ST Cluster A: Associated with a better prognosis and lower risk scores.
- ST Cluster B: Characterized by aggressive, high-risk features, advanced disease stages (III–IV), and poorer clinical outcomes.
ACTN1 and the Cys104 "Hot Spot"
Among the identified HRSGs, ACTN1 (Actinin Alpha 1) emerged as a critical regulator, showing significant upregulation in advanced tumors. Furthermore, structural analysis suggested that the Cys104 residue of the Midkine protein acts as a central hub, interacting with both LRP1 and ACTN1 within a 5 Å distance. This pinpointed Cys104 as a potential "druggable" site for future targeted therapies.
Model Performance and Immunotherapy
The 59-gene risk model demonstrated exceptional predictive power, achieving an Area Under the Curve (AUC) of >0.9 in the training cohort and maintaining high efficacy (AUC ~0.8) in independent validation sets. Notably, the model successfully identified patients in the IMvigor210 cohort who were less likely to respond to anti-PD-L1 immunotherapy, suggesting its utility in guiding personalized treatment decisions.
Discussion and Future Directions
While the findings provide a robust framework for understanding BC progression, the authors note that the study relies heavily on computational modeling and public datasets. Future "wet lab" experiments, such as CRISPR-mediated knockdowns or site-directed mutagenesis of the Cys104 residue, are essential to validate these interactions in vivo. Additionally, the discovery of Cys104 as a critical interaction site opens the door for the development of small-molecule inhibitors designed to disrupt this oncogenic complex.
In conclusion, this research highlights the MDK-LRP1 pathway as a key mediator of stemness in bladder cancer and provides a novel prognostic tool that could significantly improve patient management and therapy selection.
Summary updated